Search Results
Your search for all items matches 3195 pages
Showing 1 - 50
Julia Rotow, MD, on Metastatic HER2-Mutant NSCLC: First-Line T-DXd
Julia Rotow, MD, of Dana-Farber Cancer Institute, discusses the primary results from the phase III DESTINY-Lung04 trial, which evaluated first-line trastuzumab deruxtecan (T-DXd), a HER2-directed antibody-drug conjugate, against pembrolizumab plus platinum chemotherapy in patients with...
Martin Reck, MD, PhD, on Resectable/Borderline Resectable NSCLC: Neoadjuvant Durvalumab Plus Chemotherapy
Martin Reck, MD, PhD, of LungenClinic Grosshansdorf, reviews efficacy and safety data from the primary analysis of MDT-BRIDGE. The phase II study is investigating perioperative durvalumab plus neoadjuvant chemotherapy in patients with resectable/borderline resectable stage IIB–IIIB non–small cell...
Alexander I. Spira MD, PhD, FACP, FASCO, on Metastatic EGFR-Mutated NSCLC: Global Study of Izalontamab Brenitecan
Alexander I. Spira MD, PhD, FACP, FASCO, of Virginia Cancer Specialists and US Oncology, discusses findings from a global phase I study of izalontamab brenitecan (BL-B01D1), an antibody-drug conjugate comprising an EGFR x HER3 bispecific antibody conjugated to a novel topoisomerase 1 inhibitor...
Chul Kim, MD, on NSCLC With EGFR Exon 20 Insertions: First-Line Amivantamab/Chemotherapy vs Chemotherapy
Chul Kim, MD, of Georgetown Cancer Institute, reviews findings from the phase III PAPILLON study, which found that first-line amivantamab plus carboplatin/pemetrexed was associated with numerically longer overall survival compared with chemotherapy alone in patients with previously untreated...
Chad G. Rusthoven, MD, on SCLC: Brain MRI Surveillance With or Without Prophylactic Cranial Irradiation
Chad G. Rusthoven, MD, of the University of Colorado School of Medicine, presents results from the international phase III SWOG S1827 MAVERICK trial, which showed that brain MRI surveillance alone improved cognitive failure–free survival compared with MRI surveillance plus prophylactic cranial...
Roy S. Herbst, MD, PhD, on Resected EGFR-Mutated NSCLC: Long-Term Overall Survival With Osimertinib
Roy S. Herbst, MD, PhD, of Dartmouth Cancer Center, discusses 8-year overall survival data from the landmark ADAURA trial, which showed the sustained long-term benefit of adjuvant therapy with osimertinib for patients with completely resected, EGFR-mutated stage IB–IIIA non–small cell lung cancer...
Alexander Drilon, MD, on Advanced Metastatic ROS1-Positive NSCLC: Zidesamtinib in TKI-Naive Patients
Alexander Drilon, MD, of Memorial Sloan Kettering Cancer Center, presents efficacy and safety data from a phase II cohort of the ARROS-1 trial, which included patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC) who were naive to tyrosine kinase inhibitor...
Jennifer Gile, MD, on High-Risk DLBCL: frontMIND and POLARIX Regimens
Jennifer Gile, MD, of Willamette Valley Cancer Institute, talks about the first positive phase III trials in the high-risk diffuse large B-cell lymphoma (DLBCL) space—POLARIX and frontMIND. POLARIX established the superiority of a modified regimen of rituximab, cyclophosphamide, doxorubicin,...
Jennifer Gile, MD, on First-Line Treatment of DLBCL: POLARIX Long-Term Update and Implications
Jennifer Gile, MD, of Willamette Valley Cancer Institute, reviews findings from the POLARIX study, a double-blind, placebo-controlled, international phase III trial that evaluated pola-R-CHP—a modified regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), in...
Case 3: <em>BRCA</em>-Mutated Metastatic Prostate Cancer
This is Part 3 of Integrating Targeted Therapies in mHSPC: A Changing Treatment Landscape, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Atish D. Choudhury, MD, PhD, Karen Autio, MD, MSc, and Elizabeth M. Wulff, MD, discuss the...
Case 2: PTEN-Deficient Metastatic Prostate Cancer
This is Part 2 of Integrating Targeted Therapies in mHSPC: A Changing Treatment Landscape, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Atish D. Choudhury, MD, PhD, Karen Autio, MD, MSc, and Elizabeth M. Wulff, MD, discuss the...
Case 1: PSMA PET–Positive Metastatic Prostate Cancer
This is Part 1 of Integrating Targeted Therapies in mHSPC: A Changing Treatment Landscape, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Atish D. Choudhury, MD, PhD, Karen Autio, MD, MSc, and Elizabeth M. Wulff, MD, discuss the...
Benjamin P. Levy, MD, on Emerging Options for KRAS G12C–Mutated NSCLC: First-Line and Combination Therapies
Benjamin P. Levy, MD, of Johns Hopkins Sidney Kimmel Cancer Center, discusses research into moving KRAS G12C inhibitors from the second to the first line, as well as combining them with immunotherapies and EGFR antibodies. Some potential combinations under investigation include KRAS G12C inhibitors ...
Benjamin P. Levy, MD, on KRAS G12C–Mutated NSCLC: Current Treatment Landscape
Benjamin P. Levy, MD, of Johns Hopkins Sidney Kimmel Cancer Center, reviews currently available therapies for patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC), noting the importance of genomic testing to identify individuals eligible for treatment with these agents. He discusses...
Wassim McHayleh, MD, FACP, MBA, on Elacestrant Plus Capivasertib in ER-Positive/HER2-Negative Advanced Breast Cancer: Update From ELEVATE
Wassim McHayleh, MD, FACP, MBA, of AdventHealth Cancer Institute, provides an update from the phase Ib/II ELEVATE trial, an open-label umbrella study. This report focuses on updated safety and preliminary efficacy for elacestrant and capivasertib for patients with estrogen receptor...
Case 3: Metastatic Hepatocellular Carcinoma After Failure of First-Line Immunotherapy
This is Part 3 of First-Line HCC in Focus: Survival, Safety, and Real-World Evidence, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, James J. Harding, MD, R. Kate Kelley, MD, and Anthony El-Khoueiry, MD, discuss management of...
Case 2: Metastatic Hepatocellular Carcinoma
This is Part 2 of First-Line HCC in Focus: Survival, Safety, and Real-World Evidence, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, James J. Harding, MD, R. Kate Kelley, MD, and Anthony El-Khoueiry, MD, discuss the management of...
Case 1: Liver-Limited Hepatocellular Carcinoma
This is Part 1 of First-Line HCC in Focus: Survival, Safety, and Real-World Evidence, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, James J. Harding, MD, R. Kate Kelley, MD, and Anthony El-Khoueiry, MD, discuss treatment...
Case 3: Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
This is Part 3 of Integrating Immunotherapy Across the SCLC Spectrum, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Laura Alder, MD, Noura Choudhury, MD, and Alissa Cooper, MD, discuss second-line treatment of extensive-stage...
Case 2: De Novo Extensive-Stage Small Cell Lung Cancer
This is Part 2 of Integrating Immunotherapy Across the SCLC Spectrum, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Laura Alder, MD, Noura Choudhury, MD, and Alissa Cooper, MD, discuss the management of de novo extensive-stage...
Case 1: Limited-Stage Small Cell Lung Cancer
This is Part 1 of Integrating Immunotherapy Across the SCLC Spectrum, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Laura Alder, MD, Noura Choudhury, MD, and Alissa Cooper, MD, discuss the management of limited-stage small cell...
Case 3: Toxicity Management in ER-Positive Breast Cancer
This is Part 3 of High-Risk HR-Positive, HER2-Negative Early-Stage Breast Cancer: Bridging Evidence, Risk Identification, and Real-World Practice, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Sara Tolaney, MD, MPH, FASCO, Erica...
Case 2: High-Risk ER-Positive Early Breast Cancer With Germline BRCA Mutation
This is Part 2 of High-Risk HR-Positive, HER2-Negative Early-Stage Breast Cancer: Bridging Evidence, Risk Identification, and Real-World Practice, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Sara Tolaney, MD, MPH, FASCO, Erica...
Case 1: Understanding Risk of Recurrence in ER-Positive Early Breast Cancer
This is Part 1 of High-Risk HR-Positive, HER2-Negative Early-Stage Breast Cancer: Bridging Evidence, Risk Identification, and Real-World Practice, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Sara Tolaney, MD, MPH, FASCO, Erica...
Antonio Llombart-Cussac, MD, PhD, on ADELA: Elacestrant Plus Everolimus in ESR1-Mutated ER-Positive HER2-Negative Advanced Breast Cancer
Antonio Llombart-Cussac, MD, PhD, of Medica Scientia Innovation Research (MEDSIR), discusses the ongoing ADELA study, a double-blind, placebo-controlled, randomized phase III trial of elacestrant plus everolimus vs elacestrant plus placebo in patients with estrogen receptor (ER)-positive...
Daniel A. Ermann, MD, on First-Line Therapy for CLL: Real-World Outcomes Among Medicare Beneficiaries
Daniel A. Ermann, MD, of Huntsman Cancer Institute, University of Utah School of Medicine, presents findings from a retrospective cohort study which used a large U.S. database to evaluate clinical outcomes among Medicare beneficiaries treated with first-line therapy for chronic lymphocytic leukemia ...
Daniel A. Ermann, MD, on Two Agents in Treatment-Naive Patients With CLL: Real-World Treatment and Survival Outcomes
Daniel A. Ermann, MD, of Huntsman Cancer Institute, University of Utah School of Medicine, reviews data from a retrospective analysis that compared the real-world effectiveness of monotherapy first-line treatment for patients with chronic lymphocytic leukemia (CLL) based on overall survival and...
Michael G. Fradley, MD: How Does Atrial Fibrillation Affect Outcomes and Health-Care Utilization Among Patients With CLL?
Michael G. Fradley, MD, of the University of Pennsylvania School of Medicine, discusses findings from a study which evaluated impact of atrial fibrillation on cardiovascular outcomes (stroke, bleeding, heart failure) and health-care utilization in patients with chronic lymphocytic leukemia (CLL)...
Case 3: Patient With Richter Transformation Refractory to Pola-R-CHP
This is Part 3 of CLL Treatment Sequencing: Where Do Next-Generation BTK Inhibitors Fit?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Mazyar Shadman, MD, MPH, Inhye Ahn, MD, and Deborah M. Stephens, DO, discuss the management...
Case 2: Patient With Double-Refractory High-Risk CLL
This is Part 2 of CLL Treatment Sequencing: Where Do Next-Generation BTK Inhibitors Fit?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Mazyar Shadman, MD, MPH, Inhye Ahn, MD, and Deborah M. Stephens, DO, discuss treatment...
Case 1: Patient With BTK C481S Resistance Mutation Following Acalabrutinib/Obinutuzumab
This is Part 1 of CLL Treatment Sequencing: Where Do Next-Generation BTK Inhibitors Fit?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Mazyar Shadman, MD, MPH, Inhye Ahn, MD, and Deborah M. Stephens, DO, discuss treatment...
Jennifer A. Woyach, MD, on Pretreated Relapsed or Refractory CLL/SLL: Ongoing ROCKET-CLL Trial
Jennifer A. Woyach, MD, of The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University, discusses the ongoing, actively recruiting ROCKET-CLL trial, which is a phase III study aiming to compare the efficacy of rocbrutinib vs pirtobrutinib in patients...
Paolo Tarantino, MD, PhD, on HER2-Positive Metastatic Breast Cancer: Overall Survival by Genomic Profile
Paolo Tarantino, MD, PhD, of Dana-Farber Cancer Institute, reviews the results of a large clinicogenomic database study that looked at overall survival by genomic profile among patients with HER2-positive metastatic breast cancer. Patients with mutations in key DNA repair genes experienced a...
François-Clément Bidard, MD, PhD, on Advanced Breast Cancer With Emergent ESR1 Mutations: First-Line Option
François-Clément Bidard, MD, PhD, of Institut Curie, presents final progression-free survival 2 findings from the phase III SERENA-6 trial, which investigated the efficacy of camizestrant, a selective estrogen receptor degrader (SERD), vs continued aromatase inhibition in patients with advanced...
Gerneiva Parkinson, MD, on Time on Systemic Therapy for Patients With HR-Positive Breast Cancer and a Pathogenic Variant
Gerneiva Parkinson, MD, of Stanford Cancer Institute, discusses time on treatment for systemic therapies among women with hormone receptor (HR)-positive breast cancer and a pathogenic variant in BRCA1, BRCA2, or PALB2 (Abstract 1096).
Siddhartha Yadav, MBBS, MD, on Germline Pathogenic Variants Among Patients With Breast or Ovarian Cancer
Siddhartha Yadav, MBBS, MD, of Mayo Clinic Rochester, talks about a real-world evaluation of germline pathogenic variants in cancer predisposition genes in unselected South Asian women with breast or ovarian cancer (Abstract 10513).
Martine J. Piccart-Gebhart, MD, PhD, on Personalizing Treatments in HR-Positive/HER2-Negative Breast Cancer
Martine J. Piccart-Gebhart, MD, PhD, of Jules Bordet Institute, Université Libre de Bruxelles, reviews multiple abstracts discussing avenues of personalized treatment for patients with hormone receptor (HR)-positive, HER2-negative breast cancer, including genomic testing and systemic therapy.
Elizabeth Smyth, MD, on New Data in Gastric/Gastroesophageal Cancers
Elizabeth Smyth, MD, of Oxford NIHR Biomedical Research Centre, Churchill Hospital, discusses three major studies presented at this year’s meeting: the antibody-drug conjugate izalontamab brengitecan in recurrent or metasatic esophageal squamous cell carcinoma (Abstract 4008); the ATTRACTION-6...
Katharina C. Kaehler, MD, on Daromun in Resectable Locally Advanced Melanoma: Trial Updates
Katharina C. Kaehler, MD, of University Hospital (UKSH), Campus Kiel, presents an update on the primary outcome and sensitivity analyses from the PIVOTAL phase III trial of daromun, a combination of two fibronectin-targeting immunocytokines (L19IL2 and L19TNF), as a neoadjuvant intralesional...
Dor Abelman, BS, on Multiple Myeloma: cfDNA WGS vs Plasma Proteomics for Minimally Invasive MRD Assessment
Dor Abelman, BS, of the University of Toronto, reviews results of a comparison of two minimally invasive measurable residual disease (MRD) assays—BM-informed cfDNA whole-genome sequencing (cfWGS) and plasma proteomic MRD (EasyM)—in patients with multiple myeloma (Abstract 7546).
Jame Abraham, MD, FACP, on Update on the DESTINY-Breast05 Trial
Jame Abraham, MD, FACP, of Cleveland Clinic, provides an update on the DESTINY-Breast05 trial, which is an ongoing phase III trial investigating postneoadjuvant trastuzumab deruxtecan (T-DXd) as compared with trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with residual...
Jame Abraham, MD, FACP, on First Results of the OPTIMA Trial in Breast Cancer: Expert Perspective
Jame Abraham, MD, FACP, of Cleveland Clinic, offers his thoughts on findings from OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis), an international randomized controlled trial comparing chemotherapy decisions made with the Prosigna (PAM50) gene...
Krishnansu S. Tewari, MD, on Gynecologic Cancers: Expert Perspective on Major Data
Krishnansu S. Tewari, MD, of the University of California, Irvine, provides commentary on research presented in the oral abstract and rapid oral abstract sessions for gynecologic cancer, focusing on this year’s major trial data in endometrial, cervical, and ovarian cancers.
Rami Manochakian, MD, FASCO, on Updates on SCLC: No Longer Too Small to Ignore
Rami Manochakian, MD, FASCO, of Mayo Clinic Florida, summarizes an educational session at ASCO that reviewed the state of the field of small cell lung cancer (SCLC) treatment. After decades of limited treatment progress, advances are being seen in immunotherapies, radiation therapy, bispecific...
Christine Lovly, MD, PhD, FASCO, on Adjuvant Selpercatinib in RET Fusion–Positive Early-Stage NSCLC: Expert Perspective
Christine Lovly, MD, PhD, FASCO, of City of Hope, offers her thoughs on the findings of the LIBRETTO-432 trial, which found improved event-free survival with adjuvant selpercatinib after definitive therapy for patients with early-stage RET fusion–positive non–small cell lung cancer (NSCLC)...
Elizabeth McDonald, MD, PhD, on GLP-1 Agonists and Breast Cancer Incidence
Elizabeth McDonald, MD, PhD, of the University of Pennsylvania, discusses results from a retrospective cohort study that showed that the use of GLP-1 treatment was associated with a significantly lower incidence of breast cancer, after accounting for age, race, ethnicity, BMI, breast density, and...
Mali Barbi, MD, MS, on Endometrial Cancer: Data in dMMR Disease and B7-H4 ADCs for Advanced Disease
Mali Barbi, MD, MS, of Northwell Health Cancer Institute Center for Women's Cancer, discusses durable survival benefits shown in the NRG-GY018 trial with pembrolizumab and the RUBY trial with dostarlimab for patients with mismatch repair–deficient (dMMR) endometrial cancer. In addition, B7-H4...
Suneel Kamath, MD, on Correlation Between Blood and Tissue Tumor Mutation Burden
Suneel Kamath, MD, of Cleveland Clinic, discusses a study that found tissue tumor mutation burden (TMB) was a stronger predictor of immunotherapy outcomes than blood-based circulating tumor DNA testing, with high tissue TMB associated with a longer time to treatment failure (Abstract 2580).
Daneng Li, MD, on Tegavivint in Advanced HCC
Daneng Li, MD, of City of Hope, discusses dose-finding results from a phase I/II trial of tegavivint, a downstream Wnt/β-catenin inhibitor, in patients with advanced hepatocellular carcinoma (HCC) (Abstract 4015).
Joel W. Neal, MD, PhD, on the CHRYSALIS-2 Study in Atypical EGFR-Mutated Advanced NSCLC
Joel W. Neal, MD, PhD, of Stanford Cancer Institute, discusses updated overall survival data from cohort C of the CHRYSALIS-2 trial, which looked at first-line amivantamab plus lazertinib in previously untreated patients with atypical EGFR-mutated advanced non–small cell lung cancer (NSCLC)...
